This study had two hypotheses; First, medicated patients with MDD would have higher levels of pro-inflammatory markers (e.g., IL-6), alternation of lipid−related biomarkers and poorer endothelial function than non−depressed controls. The gene discussed is IL6; the disease is major depressive disorder.